Linsitinib (Synonyms: OSI 906; OSI-906; OSI906) |
Catalog No.GC15749
One-Click Copy Product Info
|
Linsitinib is a potent, selective, and orally bioavailable dual IGF-1R/IR kinase inhibitor, with the IC50 values of 0.035μM, and 0.075μM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 867160-71-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Linsitinib is a potent, selective, and orally bioavailable dual IGF-1R/IR kinase inhibitor, with the IC50 values of 0.035μM, and 0.075μM, respectively [1]. Linsitinib inhibits the autophosphorylation after binding of the cognate ligands to the IGF-1R and IR, and therefore blocks the IGF-I and IGF-II induced activation of downstream pathways, such as AKT and ERK signaling[2]. Linsitinib has been widely used in different cancer cell models and xenograft tumor models to inhibit tumor growth[3].
In vitro, Linsitinib treatment for 48h inhibited the proliferation of KYSE150 cells, KYSE450 cells, KYSE510 cells, and TE-7 cells with IC50 values of 22.42μM, 8.524μM, 15.83μM, and 5.669μM, respectively[4]. A 2-hour pretreatment with 20μM Linsitinib inhibited IGF-1-induced phosphorylation of IGF-1Rβ at Tyr1135, phosphorylation of Akt at Ser473, and phosphorylation of ERK in orbital fibroblasts (OFs), and reduced hyaluronic acid secretion[5]. Treatment of IGF-1R-expressing NCI-H295R cells with 31.6125μg/ml Linsitinib for 24h inhibited proliferation and induced apoptosis, accompanied by a significant increase in caspase-3/7 activity[6].
In vivo, Linsitinib treatment via oral administration at a dose of 60mg/kg/day for 10 days resulted in inhibition of tumor growth in NCI-H292 xenograft mice[7]. Intragastric administration of Linsitinib (50mg/kg/day) for 3 consecutive days significantly reduced seizure severity, prolonged seizure latency, and reduced electroencephalogram (EEG) power density in the lithium-pilocarpine rat model[8]. Intraperitoneal injection of Linsitinib (20mg/kg/day) 3 days before ischemia-reperfusion (IR) injury improved the survival of mice after renal IR injury and reduced tubulointerstitial damage and tubular necrosis[9].
References:
[1] Mulvihill M J, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor[J]. Future medicinal chemistry, 2009, 1(6): 1153-1171.
[2] Wang Y J, Zhang Y K, Kathawala R J, et al. Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance[J]. Cancers, 2014, 6(4): 1925-1952.
[3] Ji Q S, Mulvihill M, Rosenfeld-Franklin M, et al. Preclinical characterization of OSI-906: a novel IGF-1R kinase inhibitor in clinical trials[J]. Molecular Cancer Therapeutics, 2007, 6(11_Supplement): C192-C192.
[4] Kang J, Guo Z, Zhang H, et al. Dual inhibition of EGFR and IGF-1R signaling leads to enhanced antitumor efficacy against esophageal squamous cancer[J]. International Journal of Molecular Sciences, 2022, 23(18): 10382.
[5] Lee J Y, Lee S B, Yang S W, et al. Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy[J]. Plos one, 2024, 19(12): e0311093.
[6] Luffy M, Ganz A L, Wagner S, et al. Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells[J]. Frontiers in Immunology, 2024, 15: 1488220.
[7] McKinley E T, Bugaj J E, Zhao P, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer[J]. Clinical Cancer Research, 2011, 17(10): 3332-3340.
[8] Jiang G, Wang S, Chen M, et al. Linsitinib (OSI-906) modulates brain energy metabolism and seizure activity in the lithium-pilocarpine rat model[J]. Acta Epileptologica, 2021, 3(1): 19.
[9] Lyon A, Agius T, Macarthur M R, et al. Dietary or pharmacological inhibition of insulin-like growth factor-1 protects from renal ischemia-reperfusion injury in mice[J]. iScience, 2024, 27(12).
| Cell experiment [1]: | |
Cell lines | TE-7 cells |
Preparation Method | TE-7 cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum, 100units/ml penicillin, and 100μg/ml streptomycin. Cells were cultured in a 5% CO2 incubator at 37°C. TE-7 cells were seeded in 96-well plates and cultured for 24 hours. After 48 hours of treatment with various concentrations of Linsitinib (1, 2, 4, 6, 8, 10μM), 20μl MTT (5mg/ml) was added to each well and incubated for 4 hours at 37°C. Formazan was dissolved in 150μl DMSO, and the optical density at 570nm was then measured. |
Reaction Conditions | 1, 2, 4, 6, 8, 10μM; 48h |
Applications | Linsitinib treatment reduced the proliferation of TE-7 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6J mice |
Preparation Method | 10 to 12-week-old male C57BL/6J mice had ad libitum access to food and water and were housed under standard housing conditions with a 12-h light/12-h dark cycle, humidity of 30 to 70%, and temperature of 20°C-23°C. Two days before surgery and on the morning of surgery, Linsitinib (20mg/kg/day) was injected intraperitoneally every morning. Mice were anesthetized with 3% isoflurane in 2L O2 and kept at 37°C with an electrical heating pad. Following a 2-cm abdominal incision, the vascular pedicles of the right and left kidneys were identified under a microscope. First, the right renal artery, vein, and ureter were ligated and cauterized. The left pedicle was clamped for mice with vascular micro-clamps. The wound was closed, and the mouse tissues were collected for analysis on the second day after renal IR injury. |
Dosage form | 20mg/kg/day for 3 days; i.p. |
Applications | Linsitinib treatment significantly reduced IR injury in mice, inhibited histological tubulointerstitial damage, and tubular necrosis. |
References: | |
| Cas No. | 867160-71-2 | SDF | |
| Synonyms | OSI 906; OSI-906; OSI906 | ||
| Chemical Name | 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol | ||
| Canonical SMILES | CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O | ||
| Formula | C26H23N5O | M.Wt | 421.51 |
| Solubility | ≥ 21.1mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3724 mL | 11.8621 mL | 23.7242 mL |
| 5 mM | 474.5 μL | 2.3724 mL | 4.7448 mL |
| 10 mM | 237.2 μL | 1.1862 mL | 2.3724 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)